Tirzepatide for Diabetes and Obesity: A Complete Review of the Clinical Trial Evidence
Tirzepatide, the first GLP-1/GIP dual agonist, reduced HbA1c by up to 3% in diabetes and body weight by up to 22.4% in obesity — outperforming every comparator drug tested.
Quick Facts
What This Study Found
This review synthesizes the entire SURPASS and SURMOUNT-1 clinical trial programs for tirzepatide. In type 2 diabetes (SURPASS), weekly tirzepatide 5-15 mg reduced HbA1c by 1.87-3.02% and body weight by 5.4-12.9 kg over up to 104 weeks, outperforming semaglutide 1 mg, dulaglutide, insulin degludec, and insulin glargine. It also improved liver fat, blood pressure, lipids, and reduced new-onset macroalbuminuria.
In obesity without diabetes (SURMOUNT-1), tirzepatide 5-15 mg produced 16.5-22.4% body weight reduction over 72 weeks — weight loss figures that were unprecedented at the time of publication.
Key Numbers
HbA1c reduction: 1.87-3.02% · Weight loss (T2DM): 5.4-12.9 kg · Weight loss (obesity): 16.5-22.4% · Up to 104 weeks · Beat semaglutide 1 mg head-to-head
How They Did This
Narrative review summarizing the SURPASS clinical trial program (multiple phase 3 RCTs in type 2 diabetes including head-to-head comparisons with semaglutide, dulaglutide, and insulin) and the SURMOUNT-1 trial (phase 3 RCT in obesity without diabetes). Covers global and Japanese-specific populations.
Why This Research Matters
Tirzepatide was the first drug to combine GLP-1 and GIP receptor activation, and the results were transformative — HbA1c reductions of up to 3% and weight loss exceeding 20% represented a step change in what medication alone could achieve for diabetes and obesity.
The Bigger Picture
Tirzepatide's SURPASS and SURMOUNT programs established dual agonism as the new benchmark in metabolic medicine. The results demonstrated that targeting both GLP-1 and GIP receptors produces effects neither could achieve alone, opening the door to triple agonists (like retatrutide) and competing dual agonists (like mazdutide). This review captures the pivotal moment when the field shifted from 'how much can GLP-1 do' to 'what can multi-receptor targeting achieve.'
What This Study Doesn't Tell Us
As a review, this synthesizes existing trial data rather than generating new evidence. Published in early 2023, it covers SURMOUNT-1 but not later SURMOUNT trials or the cardiovascular outcome data. The semaglutide comparison used the 1 mg dose (for diabetes), not the higher 2.4 mg dose used for obesity. Some cardiometabolic benefits are secondary endpoints requiring further confirmatory studies.
Questions This Raises
- ?Does tirzepatide provide cardiovascular outcome benefits similar to or better than semaglutide?
- ?How does the 22.4% weight loss from tirzepatide compare to bariatric surgery outcomes long-term?
- ?Would comparing tirzepatide to semaglutide 2.4 mg (the obesity dose) change the competitive picture?
Trust & Context
- Key Stat:
- Up to 22.4% weight loss Tirzepatide 15 mg achieved this body weight reduction over 72 weeks in the SURMOUNT-1 obesity trial — the highest weight loss ever recorded for a medication at the time
- Evidence Grade:
- Rated strong because this review synthesizes data from multiple large phase 3 randomized controlled trials (SURPASS 1-6 and SURMOUNT-1) with active comparators and long treatment durations, representing the highest tier of clinical evidence.
- Study Age:
- Published in early 2023, this review covers the trial data that led to tirzepatide's approval. Since then, additional SURMOUNT trials and cardiovascular outcome data have been published, but the core SURPASS and SURMOUNT-1 findings reviewed here remain the foundation of tirzepatide's evidence base.
- Original Title:
- Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.
- Published In:
- Journal of obesity & metabolic syndrome, 32(1), 25-45 (2023)
- Authors:
- Sinha, Rachel, Papamargaritis, Dimitris(4), Sargeant, Jack A, Davies, Melanie J
- Database ID:
- RPEP-07394
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
In the SURPASS-2 head-to-head trial for type 2 diabetes, tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg. However, the comparison used semaglutide's diabetes dose, not the higher 2.4 mg obesity dose. Cross-trial comparisons suggest tirzepatide achieves greater weight loss, but a direct head-to-head obesity trial would provide definitive answers.
What are the main side effects of tirzepatide?
The most common side effects are gastrointestinal — nausea, diarrhea, and vomiting — similar to other GLP-1 drugs. These are generally mild to moderate and tend to improve over time. The side effect profile was consistent across the SURPASS and SURMOUNT trials.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-07394APA
Sinha, Rachel; Papamargaritis, Dimitris; Sargeant, Jack A; Davies, Melanie J. (2023). Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.. Journal of obesity & metabolic syndrome, 32(1), 25-45. https://doi.org/10.7570/jomes22067
MLA
Sinha, Rachel, et al. "Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.." Journal of obesity & metabolic syndrome, 2023. https://doi.org/10.7570/jomes22067
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Ob..." RPEP-07394. Retrieved from https://rethinkpeptides.com/research/sinha-2023-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.